Skip to main content
OpenTrials
Completed

NCT Number: NCT02089074

Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack

Use of drugs is an important factor in secondary prophylaxis after transient ischemic attack (TIA), but studies show that adherence to the prescribed drugs is often poor. This randomised controlled trial aims to investigate whether a systematic follow up of drug treatment using medication reconciliation, medication reviews and patient counselling by clinical pharmacists, improves adherence and/or decreases cardiovascular events the first three months and the first year after TIA. Patient satisfaction will also be compared between the two groups.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ischemic Attack, Transient Behavior Brain Diseases Brain Ischemia Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Health Behavior Medication Adherence Nervous System Diseases Patient Acceptance of Health Care Patient Compliance Stroke Treatment Adherence and Compliance Vascular Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kristiansund Sykehus, Kristiansund, Norway

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Probable or possible transient ischemic attack
  • Residing in Central Norway
  • Examined within 2 weeks after the onset of symptoms
  • Modified Rankin Scale 3 or less and living at home
  • enrolled in the MIDNOR-TIA study NCT02038725
  • Informed consent

Treatment and study plan

Drug use counselling

Behavioral

Primary outcomes

  1. adherence to drug treatment in secondary prevention after TIA

    Time frame: 3 months

    self reporting of adherence

Secondary outcomes

  1. adherence to drug treatment in secondary prevention after TIA

    Time frame: 1 year

    self reporting of adherence

  2. Persistence

    Time frame: 3 months

    Persistence measured by control of filled prescriptions

  3. Incidence of stroke and cardiovascular events and deaths

    Time frame: 3 months

    Measured by using data from national health registries

  4. degree of disability or dependence in the daily activities

    Time frame: 3 months

    measured by modified Rankin Scale and indirectly by level of care

  5. patient satisfaction

    Time frame: 3 months

    Measured by using data from the Norwegian Stroke Registry

  6. Persistence

    Time frame: 1 year

    Persistence measured by control of filled prescriptions

  7. Incidence of stroke and cardiovascular events and deaths

    Time frame: 1 year

    Measured by using data from national health registries

  8. degree of disability or dependence in the daily activities

    Time frame: 1 year

    measured by modified Rankin Scale and indirectly by level of care

  9. patient satisfaction

    Time frame: 1 year

    Measured by using data from the Norwegian Stroke Registry

Sponsors and collaborators

Lead sponsor

Norwegian University of Science and Technology

Other

Collaborators

  • Helse Midt-Norge
  • St. Olavs Hospital
  • Sykehusapotekene i Midt Norge

Registry information

Official study title

Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack: Adherence and Cardiovascular Events in the First Three Months

Important dates

Study start
2012
Primary completion
2015
Study completion
2016
First posted
Mar 17, 2014
Registry last updated
Mar 30, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.